FDA Accepts Gilead’s KITE-363 (CD19 x CD20 CAR-T) IND in LBCL
Here is a brief preview of this blast: On Thursday, August 19, Gilead (Kite) announced (press release) that the FDA has accepted the IND for KITE-363 (CD19 x CD20 CAR-T) in LBCL. Below, Celltelligence provides details on KITE-363's IND application while discussing potential competition KITE-363 may face upon approval.